Pudafensine DAT-SERT-NET ED(Organic)
Completed positive Data
Neuropathic pain
Completed positive Data
Female Sexual
IP2018 SERT-DAT-NET ED (Psychogenic) Completed positive Data
Female Sexual
IP2016 SERT/NET/DAT Exploratory
IP2017 DAT/SERT/NET Exploratory
DAT: Dopamine
SERT: Serotonin
NET: Norepinephrine

Initiator aims to develop safe and efficacious therapeutics. The company’s pipeline consists of three clinical programs, IPED2015, IP2018 and IPTN2021, and two in pre-clinical stage, IP2016 and IP2017.

Pudafensine (API code: IP2015) is being tested in two clinical indications: i) erectile dysfunction (organic) (Program called IPED2015) and ii) Neuropathic pain (program called IPTN2021). IP2018 drug candidate is so far only being tested in one clinical indication: erectile dysfunction (psychogenic ie. caused by depression, low mood or anxiety – or caused by the pharmacological therapies these patients receive) (Program called IP2018). All drug candidates belong to the drug class known as monoamine reuptake inhibitors and is based on compounds modulating monoamine neurotransmitters e.g., dopamine, noradrenaline, and serotonin.

Modulation and regulation of monoamines are indeed validated and efficacious therapy for a broad range of medical conditions. The monoaminergic system plays a pivotal role in many important physiological functions, e.g., mood, pain, arousal, sexual function, and might be used to treat depression, attention deficit hyperactive disorder (ADHD), narcolepsy, and anxiety. The major challenge with targeting the monoaminergic system is ensuring that the modulation is a safe, without the adverse effects (AEs) known from previously and currently marketed monoamine modulation drugs, e.g., liver tox and sexual dysfunction. Initiator Pharma has a pipeline of clearly differentiated monoamine modulation drug candidates with attractive safety profiles.

*IP2015 API